SER Serina Therapeutics, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1708599 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY132.1%
TTM net income YoY-72.2%
TTM EPS YoY-26.5%
Revenue 3-yr CAGR56.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-18,478.5%
Net margin-14,755.4%
FCF margin-13,856.9%
EBITDA margin-18,439.2%
Returns
ROE-6,351.7%
ROA-280.5%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets100.5%
Debt / equity—
Current ratio1.71x
Interest coverage-112.78x
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-17.9%
Payout ratio—
Capex / revenue45.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $130,000 | $56,000 | $3.15M | $34,000 | $144,000 |
| Cost of revenue | — | — | $40,000 | $13,000 | $19,000 |
| Gross profit | — | — | $102,000 | $21,000 | $125,000 |
| R&D expense | $13.15M | $7.48M | $2.39M | $1.02M | $1.46M |
| SG&A expense | $11.00M | $9.62M | $3.89M | $5.97M | $6.71M |
| Operating income | -$24.02M | -$17.05M | -$3.13M | -$6.97M | -$7.93M |
| Interest expense | $213,000 | $526,000 | $558,000 | $3.33M | $1.10M |
| Pretax income | -$19.20M | -$11.21M | $5.27M | $10.50M | $8.70M |
| Income tax | $18,000 | $0 | $0 | — | — |
| Net income | -$19.18M | -$11.14M | $5.27M | -$10.46M | -$8.68M |
| EBITDA | -$23.92M | -$16.95M | -$3.04M | — | — |
| EPS (basic) | -1.91 | -1.51 | 2.36 | -9.70 | -0.23 |
| EPS (diluted) | -1.91 | -1.51 | 0.73 | -9.70 | -0.23 |
| Weighted avg. shares (diluted) | 10.19M | 7.36M | 7.35M | 1,079 | 37.89M |
| Balance sheet | |||||
| Cash & equivalents | $3.06M | $3.67M | $7.62M | $645,000 | $584,000 |
| Receivables | — | — | $57,000 | $4,000 | $25,000 |
| Current assets | $6.08M | $5.68M | $7.62M | $2.45M | $2.23M |
| PP&E, net | $465,000 | $501,000 | $573,000 | — | — |
| Intangibles | — | — | $0 | $738,000 | $870,000 |
| Total assets | $6.95M | $6.72M | $8.97M | $3.24M | $3.15M |
| Current liabilities | $3.56M | $2.37M | $1.41M | $10.08M | $8.97M |
| Long-term debt | — | — | — | $18.12M | $13.20M |
| Total debt | — | — | — | $18.12M | $13.20M |
| Total liabilities | $6.99M | $6.22M | $4.86M | $20.56M | $15.03M |
| Shareholders' equity | -$37,000 | $641,000 | -$32.29M | -$37.78M | -$11.83M |
| Net debt | — | — | — | $17.48M | $12.62M |
| Shares outstanding | 10.77M | 9.42M | 2.41M | 1.08M | 37.94M |
| Cash flow statement | |||||
| Operating cash flow | -$17.95M | -$17.14M | -$2.48M | -$5.94M | -$7.86M |
| Capital expenditure | $59,000 | $22,000 | $504,000 | — | — |
| Free cash flow | -$18.01M | -$17.16M | -$2.98M | — | — |
| Investing cash flow | -$59,000 | -$22,000 | -$504,000 | — | $666,000 |
| Financing cash flow | $17.41M | $13.21M | $10.07M | $6.00M | $7.25M |
| Depreciation & amortization | $100,000 | $100,000 | $90,000 | — | — |
| Stock-based compensation | $3.79M | $2.60M | $25,000 | $760,000 | $999,000 |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.